Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Bone Remodeling01:40

Bone Remodeling

38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

After Hours, After Thought? Rethinking CT Stewardship in Pediatric Head Trauma.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same author

Pediatric Playground Trauma.

Radiographics : a review publication of the Radiological Society of North America, Inc·2025
Same author

Invited Commentary: Code Stroke in Children: Time Is Brain in the Young Ones, Too.

Radiographics : a review publication of the Radiological Society of North America, Inc·2025
Same author

Abnormal Pancreaticobiliary Junction in Children: Frequency on Magnetic Resonance Cholangiopancreatography and Associated Pancreaticobiliary Diseases.

Investigative radiology·2025
Same author

Invited Commentary: Liver Masses in Children with Underlying Predispositions: The Need for Multidisciplinary Collaboration.

Radiographics : a review publication of the Radiological Society of North America, Inc·2024
Same author

Neonatal Liver Imaging: Techniques, Role of Imaging, and Indications.

Radiographics : a review publication of the Radiological Society of North America, Inc·2024

Related Experiment Video

Updated: Jun 28, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

17.5K

Denosumab-induced bone changes in a child: a case report.

Caroline Rutten1, Claudia Martinez-Rios1, Alan Daneman2

  • 1Department of Diagnostic Imaging, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada.

Pediatric Radiology
|April 20, 2024
PubMed
Summary

Denosumab therapy for jaw lesions caused significant bone changes in a young girl. This case highlights potential skeletal side effects of denosumab in pediatric patients.

Keywords:
ChildDenosumabGiant cell tumorOsseous sclerosisRANKLRadiography

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.2K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.2K

Related Experiment Videos

Last Updated: Jun 28, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

17.5K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.2K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.2K

Area of Science:

  • Oncology
  • Orthopedics
  • Pharmacology

Background:

  • Giant cell lesions of the jaw are rare bone tumors.
  • Denosumab is a monoclonal antibody used to treat various bone conditions, including giant cell tumors.

Observation:

  • A 9-year-old girl received denosumab for two years to treat giant cell lesions of the jaw.
  • Following treatment, she exhibited notable alterations in bone structure.

Findings:

  • The patient developed striking bone changes attributed to denosumab therapy.
  • These changes represent a potential adverse skeletal effect of denosumab.

Implications:

  • This case underscores the importance of monitoring skeletal health in pediatric patients undergoing denosumab treatment.
  • Further research is needed to understand the long-term skeletal consequences of denosumab in children.
  • Clinicians should consider the potential for denosumab-induced bone abnormalities when managing pediatric bone lesions.